Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DMAC - DiaMedica Therapeutics Inc.


IEX Last Trade
5.385
-0.045   -0.836%

Share volume: 916
Last Updated: Thu 26 Dec 2024 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%

$5.43
-0.05
-0.83%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
22%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 16%
Company vs Stock growth
vs
Performance
5 Days
-2.14%
1 Month
3.54%
3 Months
22.33%
6 Months
77.70%
1 Year
85.87%
2 Year
243.79%
Key data
Stock price
$5.38
P/E Ratio 
0.00
DAY RANGE
$5.21 - $5.45
EPS 
$0.00
52 WEEK RANGE
$2.29 - $6.41
52 WEEK CHANGE
$80.76
MARKET CAP 
167.999 M
YIELD 
N/A
SHARES OUTSTANDING 
42.748 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
0.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$112,098
AVERAGE 30 VOLUME 
$116,606
Company detail
CEO: Rick J. Pauls
Region: US
Website: diamedica.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

DiaMedica Therapeutics Inc. develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein. DM199 is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes.

Recent news